Amendment and Mail Process Complete

ABECMA

Celgene Corporation

Amendment and Mail Process Complete

Trademark Snap Shot Amendment & Mail Processing Stylesheet
(Table presents the data on Amendment & Mail Processing Complete)

OVERVIEW

SERIAL NUMBER 88202247 FILING DATE 11/21/2018
REG NUMBER 0000000 REG DATE N/A
REGISTER PRINCIPAL MARK TYPE TRADEMARK
INTL REG # N/A INTL REG DATE N/A
TM ATTORNEY EL-BAYEH, ALEXANDRA E
L.O. ASSIGNED N60-NOT FOUND

PUB INFORMATION

RUN DATE 09/06/2019
PUB DATE N/A
STATUS 661-RESPONSE AFTER NON-FINAL-ACTION-ENTERED
STATUS DATE 09/05/2019
LITERAL MARK ELEMENT ABECMA

DATE ABANDONED N/A DATE CANCELLED N/A
SECTION 2F NO SECTION 2F IN PART NO
SECTION 8 NO SECTION 8 IN PART NO
SECTION 15 NO REPUB 12C N/A
RENEWAL FILED NO RENEWAL DATE N/A
DATE AMEND REG N/A


FILING BASIS

FILED BASIS CURRENT BASIS AMENDED BASIS
1 (a) NO 1 (a) NO 1 (a) NO
1 (b) YES 1 (b) NO 1 (b) NO
44D YES 44D NO 44D NO
44E NO 44E YES 44E NO
66A NO 66A NO

NO BASIS NO NO BASIS NO


MARK DATA

STANDARD CHARACTER MARK YES
LITERAL MARK ELEMENT ABECMA
MARK DRAWING CODE 4-STANDARD CHARACTER MARK
COLOR DRAWING FLAG NO

CURRENT OWNER INFORMATION

PARTY TYPE 10-ORIGINAL APPLICANT
NAME Celgene Corporation
ADDRESS 86 Morris Avenue
Summit, NJ 07901
ENTITY 03-CORPORATION
CITIZENSHIP Delaware

GOODS AND SERVICES

INTERNATIONAL CLASS 005
          DESCRIPTION TEXT Pharmaceutical preparations for use in the treatment of multiple myeloma, blood disease, cancer, diseases in the fields of oncology, immunology and inflammation; pharmaceutical preparations, namely, cytokine inhibitory drugs; pharmaceutical preparations that modulate the immune system

GOODS AND SERVICES CLASSIFICATION

INTERNATIONAL CLASS 005 FIRST USE DATE NONE FIRST USE IN COMMERCE DATE NONE CLASS STATUS 6-ACTIVE

MISCELLANEOUS INFORMATION/STATEMENTS

CHANGE IN REGISTRATION NO


FOREIGN INFORMATION
PRIORITY CLAIMED SEC. 44(D) ON United Kingdom
APPLICATION NO. UK0000335501
APPLICATION FILING DATE 11/21/2018
FOREIGN REG NO. 00003355015
FOREIGN REG DATE 11/20/2018
FOREIGN RNWL NUM N/A
DATE OF FOREIGN RNWL N/A
FOREIGN EXPIRATION 11/20/2028
FOREIGN RNWL EXPIRATION N/A

PROSECUTION HISTORY

DATE ENT CD ENT TYPE DESCRIPTION ENT NUM
09/05/2019 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED 012
09/05/2019 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE 011
09/03/2019 ALIE A ASSIGNED TO LIE 010
08/22/2019 ALIE A ASSIGNED TO LIE 009
08/14/2019 ERSI I TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED 008
02/26/2019 GNS3 O NOTIFICATION OF LETTER OF SUSPENSION E-MAILED 007
02/26/2019 GNSL F LETTER OF SUSPENSION E-MAILED 006
02/26/2019 CNSL R SUSPENSION LETTER WRITTEN 005
02/25/2019 DOCK D ASSIGNED TO EXAMINER 004
02/22/2019 PARI I TEAS VOLUNTARY AMENDMENT RECEIVED 003
12/11/2018 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM 002
11/24/2018 NWAP I NEW APPLICATION ENTERED IN TRAM 001

CURRENT CORRESPONDENCE INFORMATION

ATTORNEY Camille M. Miller
CORRESPONDENCE ADDRESS Camille M. Miller
Cozen O'Connor
1650 Market Street
Suite 2800
Philadelphia, PA 19103
DOMESTIC REPRESENTATIVE NONE

Amendment and Mail Process Complete [image/jpeg]


uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed